ATE241696T1 - Rekombinanter hiv-spezifischer impfstoff aus poxviru - Google Patents

Rekombinanter hiv-spezifischer impfstoff aus poxviru

Info

Publication number
ATE241696T1
ATE241696T1 AT92914713T AT92914713T ATE241696T1 AT E241696 T1 ATE241696 T1 AT E241696T1 AT 92914713 T AT92914713 T AT 92914713T AT 92914713 T AT92914713 T AT 92914713T AT E241696 T1 ATE241696 T1 AT E241696T1
Authority
AT
Austria
Prior art keywords
virus
poxviru
immunodeficiency virus
recombinant hiv
specific vaccine
Prior art date
Application number
AT92914713T
Other languages
English (en)
Inventor
Enzo Paoletti
James Tartaglia
William I Cox
Robert Gallo
Genoveffa Franchini
Original Assignee
Virogenetics Corp
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp, Us Gov Health & Human Serv filed Critical Virogenetics Corp
Application granted granted Critical
Publication of ATE241696T1 publication Critical patent/ATE241696T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92914713T 1991-06-14 1992-06-12 Rekombinanter hiv-spezifischer impfstoff aus poxviru ATE241696T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71592191A 1991-06-14 1991-06-14
US89738292A 1992-06-11 1992-06-11
PCT/US1992/005107 WO1992022641A1 (en) 1991-06-14 1992-06-12 Immunodeficiency virus recombinant poxvirus vaccine

Publications (1)

Publication Number Publication Date
ATE241696T1 true ATE241696T1 (de) 2003-06-15

Family

ID=27109438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914713T ATE241696T1 (de) 1991-06-14 1992-06-12 Rekombinanter hiv-spezifischer impfstoff aus poxviru

Country Status (8)

Country Link
EP (2) EP0592546B1 (de)
JP (1) JP3504659B2 (de)
AT (1) ATE241696T1 (de)
AU (3) AU672581B2 (de)
CA (1) CA2110489A1 (de)
DE (1) DE69233080T2 (de)
DK (1) DK0592546T3 (de)
WO (1) WO1992022641A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
AU702634B2 (en) * 1991-03-07 1999-02-25 Virogenetics Corporation Immunodeficiency recombinant poxvirus
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
JPH06505397A (ja) * 1991-03-20 1994-06-23 ヴァイロジェネティクス　コーポレイション マラリア組換体ポックスウイルス
EP0592546B1 (de) * 1991-06-14 2003-05-28 Virogenetics Corporation Rekombinanter hiv-spezifischer impfstoff aus poxviru
AU680609B2 (en) * 1992-01-13 1997-08-07 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0696204A4 (de) * 1993-02-26 1999-03-31 Syntro Corp Rekombinierter geflügelpockenvirus und seine verwendung
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
KR100325554B1 (ko) 1993-03-26 2002-11-02 젠-프로브 인코포레이티드 사람의면역결핍 바이러스타입1의검출
BR9406821A (pt) * 1993-06-09 1996-03-26 Connaught Lab Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo
FR2720077B1 (fr) * 1994-05-18 1996-08-09 Univ Rennes Procédé d'amplification enzymatique in vitro d'un fragment d'ADN à l'aide d'amorces en escalier.
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
AUPP700798A0 (en) * 1998-11-09 1998-12-03 Australian National University, The Recombinant viral constructs and methods relating thereto
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP1450854A2 (de) 2001-11-30 2004-09-01 Isis Innovation Limited Impfstoff
ITFI20050098A1 (it) * 2005-05-10 2006-11-11 Domenico Acanfora Composizione farmaceutica per il trattamento della immunodeficienza acquisita
GB2460694A (en) * 2008-06-06 2009-12-09 Secr Defence Attenuated poxviruses
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
RU2609769C2 (ru) 2011-04-06 2017-02-02 Биоваксим Лимитед Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
EP2788021B1 (de) 2011-12-09 2017-01-18 Bavarian Nordic A/S Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
WO1990010693A1 (en) * 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
GB8907468D0 (en) * 1989-04-03 1989-05-17 Smith Geoffrey L Vaccinia vectors,vaccinia genes and expression products thereof
IE68404B1 (en) * 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine
EP0563323A4 (en) * 1990-12-19 1996-02-28 Epitope Inc Hiv reverse transcriptase vaccine
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
EP0592546B1 (de) * 1991-06-14 2003-05-28 Virogenetics Corporation Rekombinanter hiv-spezifischer impfstoff aus poxviru

Also Published As

Publication number Publication date
EP0592546A1 (de) 1994-04-20
EP1156102A1 (de) 2001-11-21
AU716480B2 (en) 2000-02-24
AU672581B2 (en) 1996-10-10
WO1992022641A1 (en) 1992-12-23
JP3504659B2 (ja) 2004-03-08
CA2110489A1 (en) 1992-12-23
DE69233080D1 (de) 2003-07-03
EP0592546A4 (de) 1994-10-12
AU712431B2 (en) 1999-11-04
EP0592546B1 (de) 2003-05-28
DE69233080T2 (de) 2004-04-15
AU6564696A (en) 1997-02-13
JPH06508037A (ja) 1994-09-14
DK0592546T3 (da) 2003-09-15
AU2259792A (en) 1993-01-12
AU6564596A (en) 1997-02-13

Similar Documents

Publication Publication Date Title
ATE241696T1 (de) Rekombinanter hiv-spezifischer impfstoff aus poxviru
GB2269820A (en) Flavivirus recombinant poxvirus vaccine
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
CA2014465A1 (en) Herpesvirus recombinant poxvirus vaccine
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
DK1335987T3 (da) Modificeret vacciniavirus Ankara variant
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
ATE154808T1 (de) Peptide mit den immunologischen eigenschaften von hiv-2
ATE241014T2 (de) Hiv-2 varianten
DK0437604T3 (da) Rekombinant poxvirus- og streptokok M-proteinvaccine
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
ATE359089T1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis-b-virus
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
KR950005326A (ko) 재조합 아데노바이러스 백신
DE59208622D1 (de) Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
PT623172E (pt) Vacina de virus vaccinia recombinante do virus da doenca de marek
RU94010320A (ru) Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0592546

Country of ref document: EP

REN Ceased due to non-payment of the annual fee